The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why should we use the BL-IPI for prognosis of patients with Burkitt lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Adam Olszewski, Brown University, Providence, US, about the use of the Burkitt Lymphoma International Prognostic Index for the prognosis of patients with Burkitt lymphoma.

Why should we use the BL-IPI for prognosis of patients with Burkitt lymphoma?

In this video, Olszewski talks about the development and validation of a novel prognostic index specific to Burkitt lymphoma.

Share: